Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.

View/ Open
Date
2018-11ICR Author
Author
Cristofanilli, M
DeMichele, A
Giorgetti, C
Turner, NC
Slamon, DJ
Im, S-A
Masuda, N
Verma, S
Loi, S
Colleoni, M
Theall, KP
Huang, X
Liu, Y
Bartlett, CH
Type
Journal Article
Metadata
Show full item recordAbstract
Background The addition of palbociclib to fulvestrant improved clinical outcomes over placebo-fulvestrant in endocrine-pretreated metastatic breast cancer (MBC) patients in PALOMA-3. Here, we examined factors predictive of long-term benefit.Methods Premenopausal-peri/postmenopausal patients with endocrine-resistant, hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative MBC were randomised 2:1 to fulvestrant (500 mg) and either palbociclib (125 mg/d; 3/1 schedule; n = 347) or placebo (n = 174). Baseline characteristics, mutation status and HR expression levels were compared in patients with and without prolonged benefit (treatment duration ≥18 months).Results By August 2016, 100 patients (29%) on palbociclib-fulvestrant and 26 (15%) on placebo-fulvestrant demonstrated prolonged benefit, with long-term responders in both arms sharing common clinical characteristics. They usually had less disease burden at baseline versus those treated <18 months, such as having one disease site (40% vs 29% on palbociclib-fulvestrant and 69% vs 29% on placebo-fulvestrant), bone-only disease (32% vs 22% and 46% vs 17%) and were less heavily pretreated (69% vs 56% and 73% vs 60% had ≤2 prior therapies). Baseline tumour ESR1 and PIK3CA mutation rates were lower among long-term responders in both arms; median oestrogen receptor H-scores were similar, whereas progesterone receptor H-scores were higher among long-term responders.Conclusions This exploratory analysis demonstrates that some patients with endocrine-resistant MBC derive significant and prolonged benefit when treated with palbociclib-fulvestrant, with fewer patients experiencing similar efficacy with placebo-fulvestrant. The current analysis did not identify specific molecular or clinical factors prognostic of long-term benefit with palbociclib-fulvestrant (ClinicalTrials.gov, NCT01942135).
Collections
Subject
Humans
Carcinoma
Breast Neoplasms
Neoplasms, Hormone-Dependent
Piperazines
Pyridines
Progesterone
Receptor, erbB-2
Neoplasm Proteins
Receptors, Estrogen
Receptors, Progesterone
Antineoplastic Agents, Hormonal
Antineoplastic Combined Chemotherapy Protocols
Estrogens
Disease-Free Survival
Proportional Hazards Models
Follow-Up Studies
Double-Blind Method
Drug Resistance, Neoplasm
Adult
Aged
Aged, 80 and over
Middle Aged
Female
Kaplan-Meier Estimate
Fulvestrant
Progression-Free Survival
Research team
Molecular Oncology
Language
eng
Date accepted
2018-08-16
License start date
2018-11
Citation
European journal of cancer (Oxford, England : 1990), 2018, 104 pp. 21 - 31
Except where otherwise noted, this item's license is described
as
https://creativecommons.org/licenses/by/4.0
Related items
Showing items related by title, author, creator and subject.
-
Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial.
Detre, SI; Ashley, S; Mohammed, K; Smith, IE; Powles, TJ; et al. (2017-03)The randomized, double-blinded Royal Marsden Tamoxifen Breast Cancer Prevention Trial in healthy high-risk women started in 1986 and is still blinded. Eligible participants (<i>n</i> = 2,471) were randomly assigned to ... -
IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.
Calcinotto, A; Spataro, C; Zagato, E; Di Mitri, D; Gil, V; et al. (2018-07)Patients with prostate cancer frequently show resistance to androgen-deprivation therapy, a condition known as castration-resistant prostate cancer (CRPC). Acquiring a better understanding of the mechanisms that control ... -
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Di Leo, A; Johnston, S; Lee, KS; Ciruelos, E; Lønning, PE; et al. (2018-01)BACKGROUND:Activation of the PI3K/AKT/mTOR pathway occurs frequently in breast cancer that is resistant to endocrine therapy. Approved mTOR inhibitors effectively inhibit cell growth and proliferation but elicit AKT ...